Vitamin D, PTH, and calcium and the risk of prostate cancer: A prospective nested case-control study

Cancer Causes and Control

Volumn 23, Issue 8, 2012, Pages 1377-1385

  Brändstedt, Johan ^a   Almquist, Martin ^a,b   Manjer, Jonas ^a,b   Malm, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Calcium; Nested case control study; Prospective; Prostate cancer; PTH; Vitamin D

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ALBUMIN; CALCIFEDIOL; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; TREND STUDY; VITAMIN BLOOD LEVEL;

AGED; CALCIUM; CASE-CONTROL STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SWEDEN; VITAMIN D;

EID: 84864884130     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9948-3     Document Type: Article

References (46)

1. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859-864
2. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10(5A): 1307-1311
3. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D (2007) Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 22(Suppl 2):V74-V80
4. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6(9):727-732
5. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11(9): 847-852
6. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108(1):104-108
7. Albanes D, Weinstein SJ, Mondul AM, Virtamo J (2011) Circulating Vitamin D and risk of prostate cancer-response. Cancer Epidemiol Biomarkers Prev. Epub 2011/11/03
8. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT et al (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2(5):467-472
9. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5(2):121-126
10. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89-90(1-5):533-537
11. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D et al (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103
12. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A et al (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425-432
13. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255-265
14. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414-1424
15. Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Metaanalysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33(6):435-445
16. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30(3):183-187
17. Liao J, Schneider A, Datta NS, McCauley LK (2006) Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 66(18):9065-9073
18. Fedirko V, Riboli E, Bueno-de-Mesquita HB, Rinaldi S, Pischon T, Norat T, et al. Pre-diagnostic circulating parathyroid hormone concentration and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Cancer Epidemiol Biomarkers Prev
19. Schwartz GG (2008) Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17(3):478-483. Epub 2008/03/20
20. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (2001) Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86(9):4133-4138. Epub 2001/09/11
21. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA et al (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58(3):442-447
22. Skinner HG, Schwartz GG (2009) A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 18(2):575-578
23. Skinner HG, Schwartz GG (2008) Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 17(9):2302-2305. Epub 2008/09/05
24. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571-1578
25. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675-684
26. Halthur C, Johansson AL, Almquist M, Malm J, Gronberg H, Manjer J et al (2009) Serum calcium and the risk of prostate cancer. Cancer Causes Control 20(7):1205-1214
27. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10(6):489-499
28. Wallstrom P (2002) Diet, lifestyle, antioxidants and biomarkers of cancer risk. An epidemiological report from the Malmö Diet and cancer cohort. Thesis, Lund University, Malmö
29. Anker P, Wieland E, Ammann D, Dohner RE, Asper R, Simon W (1981) Neutral carrier based ion-selective electrode for the determination of total calcium in blood serum. Anal Chem 53(13):1970-1974
30. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP et al (2007) The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 85(3):649-650
31. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100(11): 796-804
32. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289(1):F8-F28
33. Pero RW, Olsson A, Bryngelsson C, Carlsson S, Janzon L, Berglund G et al (1998) Quality control program for storage of biologically banked blood specimens in the Malmo Diet and Cancer Study. Cancer Epidemiol Biomarkers Prev 7(9):803-808
34. Hollis BW (2008) Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 88(2):507S-510S
35. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV et al (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 59(7):491-500
36. Gallagher SK, Johnson LK, Milne DB (1989) Short-term and long-term variability of indices related to nutritional status. I: Ca, Cu, Fe, Mg, and Zn. Clin Chem 35(3):369-373
37. Ankrah-Tetteh T, Wijeratne S, Swaminathan R (2008) Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1. Ann Clin Biochem 45(Pt 2): 167-169
38. Viljoen A, Singh DK, Twomey PJ, Farrington K (2008) Analytical quality goals for parathyroid hormone based on biological variation. Clin Chem Lab Med 46(10):1438-1442
39. Nilsson-Ehle P (2003) Laurells klinisk kemi i praktisk medicin: Studentlitteratur AB
40. Leifsson BG, Ahren B (1996) Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 81(6):2149-2153. Epub 1996/06/01
41. Kukreja SC, Shanmugam A, Lad TE (1988) Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 43(6):340-345. Epub 1988/12/01
42. Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27-33
43. Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C (2009) Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health 6(10):2585-2607
44. Hoffman RM, Stone SN, Espey D, Potosky AL (2005) Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 5:27
45. Lund Oci (2006) Kvalitetsregister för prostatacancer, Regional rapport för diagnosår 2006, Södra sjukvårdsregionen
46. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al (2011) Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PloS one 6(4):e18625. Epub 2011/04/16